696 / 1084
Patients with resectable gastric or gastro-oesophageal junction cancer who had
clinical stage
cT2 or higher
,
nodal positive (cN+)
disease,
or both
3 preoperative and 3 postoperative 3-week cycles of
ECF/ECX
or 4 preoperative and 4
postoperative
FLOT
(2-week cycles of
docetaxel
50 mg/m², intravenous
oxaliplatin
85 mg/m²,
intravenous
leucovorin
200 mg/m², and
5-FU
2600 mg/m² as a 24 h infusion, all on day 1)
Primary endpoint
:
pathological complete regression
(
TRG1a
:
equivalent to pathological
complete regression; no residual tumour cells
)
03/27/2017